Indian Council Medical Research (ICMR) - National Centre for Disease Informatics and Research (NCDIR), Nirmal Bhawan-ICMR Complex (II Floor), Poojanahalli, Kannamangala Post, Bengaluru, Karnataka, 562 110, India.
National Health Mission, Bengaluru, Karnataka, India.
BMC Cancer. 2022 May 11;22(1):527. doi: 10.1186/s12885-022-09578-1.
Cancer is the major cause of morbidity and mortality worldwide. The cancer burden varies within the regions of India posing great challenges in its prevention and control. The national burden assessment remains as a task which relies on statistical models in many developing countries, including India, due to cancer not being a notifiable disease. This study quantifies the cancer burden in India for 2016, adjusted mortality to incidence (AMI) ratio and projections for 2021 and 2025 from the National Cancer Registry Program (NCRP) and other publicly available data sources.
Primary data on cancer incidence and mortality between 2012 and 2016 from 28 Population Based Cancer Registries (PBCRs), all-cause mortality from Sample Registration Systems (SRS) 2012-16, lifetables and disability weight from World Health Organization (WHO), the population from Census of India and cancer prevalence using the WHO-DisMod-II tool were used for this study. The AMI ratio was estimated using the Markov Chain Monte Carlo method from longitudinal NCRP-PBCR data (2001-16). The burden was quantified at national and sub-national levels as crude incidence, mortality, Years of Life Lost (YLLs), Years Lived with Disability (YLDs) and Disability Adjusted Life Years (DALYs). The projections for the years 2021 and 2025 were done by the negative binomial regression model using STATA.
The projected cancer burden in India for 2021 was 26.7 million DALYs and expected to increase to 29.8 million in 2025. The highest burden was in the north (2408 DALYs per 100,000) and northeastern (2177 DALYs per 100,000) regions of the country and higher among males. More than 40% of the total cancer burden was contributed by the seven leading cancer sites - lung (10.6%), breast (10.5%), oesophagus (5.8%), mouth (5.7%), stomach (5.2%), liver (4.6%), and cervix uteri (4.3%).
This study demonstrates the use of reliable data sources and DisMod-II tools that adhere to the international standard for assessment of national and sub-national cancer burden. A wide heterogeneity in leading cancer sites was observed within India by age and sex. The results also highlight the need to focus on non-leading sites of cancer by age and sex. These findings can guide policymakers to plan focused approaches towards monitoring efforts on cancer prevention and control. The study simplifies the methodology used for arriving at the burden estimates and thus, encourages researchers across the world to take up similar assessments with the available data.
癌症是全球发病率和死亡率的主要原因。印度各地区的癌症负担存在差异,这给癌症的预防和控制带来了巨大挑战。由于癌症不是法定报告疾病,因此国家负担评估仍然是许多发展中国家(包括印度)的一项任务,这些国家依赖统计模型来进行评估。本研究利用来自国家癌症登记计划(NCRP)和其他公开数据源的 2016 年印度癌症负担数据、调整死亡率与发病率(AMI)比值以及 2021 年和 2025 年的预测数据,对印度的癌症负担进行了量化。
本研究使用了 2012 年至 2016 年来自 28 个基于人群的癌症登记处的癌症发病率和死亡率的原始数据、2012-16 年抽样登记系统(SRS)的全因死亡率、世界卫生组织(WHO)的生命表和残疾权重、印度人口普查的人口数据以及使用世界卫生组织疾病模型工具(WHO-DisMod-II)获得的癌症患病率数据。使用纵向 NCRP-PBCR 数据(2001-16 年)中的马尔可夫链蒙特卡罗方法估计 AMI 比值。在国家和次国家层面,使用粗发病率、死亡率、生命损失年(YLLs)、残疾生存年(YLDs)和残疾调整生命年(DALYs)来量化负担。使用 STATA 中的负二项回归模型对 2021 年和 2025 年的预测数据进行了预测。
预计印度 2021 年的癌症负担将达到 2670 万残疾调整生命年(DALYs),并预计到 2025 年将增加到 2980 万。该国北部(每 10 万人 2408 个 DALYs)和东北部(每 10 万人 2177 个 DALYs)地区的负担最重,男性负担更高。七个主要癌症部位——肺癌(10.6%)、乳腺癌(10.5%)、食管癌(5.8%)、口腔癌(5.7%)、胃癌(5.2%)、肝癌(4.6%)和宫颈癌(4.3%)——占总癌症负担的 40%以上。
本研究展示了使用可靠的数据来源和符合国际标准的 DisMod-II 工具来评估国家和次国家癌症负担的方法。在印度,按年龄和性别观察到主要癌症部位存在广泛的异质性。结果还强调了需要根据年龄和性别关注非主要癌症部位。这些发现可以为政策制定者规划有针对性的方法来监测癌症预防和控制工作提供指导。本研究简化了用于得出负担估计的方法,从而鼓励世界各地的研究人员使用现有数据进行类似的评估。